Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.
10.1016/S1875-5364(15)30051-0
- Author:
Jun-Xian YU
1
,
2
;
Sukesh VORUGANTI
1
,
3
;
Dan-Dan LI
4
;
Jiang-Jiang QIN
1
,
3
;
Subhasree NAG
5
;
Su XU
6
;
Sadanandan E VELU
6
;
Wei WANG
1
,
7
;
Ruiwen ZHANG
1
,
8
Author Information
1. Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
2. Center for Drug Evaluation, China Food and Drug Administration, Beijing 100038, China.
3. China Pharmaceutical University, Nanjing 210009, China.
4. Center for Drug Evaluation, China Food and Drug Administration, Beijing 100038, China.
5. Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
6. China National Institutes for Food and Drug Control, Beijing 100035, China.
7. China Pharmaceutical University, Nanjing 210009, China. Electronic address: wwei.wang@ttuhsc.edu.
8. China Pharmaceutical University, Nanjing 210009, China. Electronic address: ruiwen.zhang@ttuhsc.edu.
- Publication Type:Journal Article
- Keywords:
LC-MS/MS;
Makaluvamine analogs;
Pharmacokinetics;
Rat plasma;
TCBA-TPQ
- MeSH:
Animals;
Antineoplastic Agents;
blood;
pharmacokinetics;
Chromatography, High Pressure Liquid;
methods;
Pyrroles;
blood;
pharmacokinetics;
Quinolones;
blood;
pharmacokinetics;
Rats, Sprague-Dawley;
Tandem Mass Spectrometry;
methods
- From:
Chinese Journal of Natural Medicines (English Ed.)
2015;13(7):554-560
- CountryChina
- Language:English
-
Abstract:
We have recently designed and synthesized several novel iminoquinone anticancer agents that have entered preclinical development for the treatment of human cancers. Herein we developed and validated a quantitative HPLC-MS/MS analytical method for one of the lead novel anticancer makaluvamine analog, TCBA-TPQ, and conducted a pharmacokinetic study in laboratory rats. Our results indicated that the HPLC-MS/MS method was precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of TCBA-TPQ and plasma pharmacokinetics in rats. Our results provide a basis for future preclinical and clinical development of this promising anticancer marine analog.
